LONDON, Oct 3 (Reuters) – Britain’s AstraZeneca said
it had licensed a potential medicine for inflammatory diseases
to Allergan for an upfront payment of $250 million and
potential additional…
The post AstraZeneca licenses inflammatory disease candidate to Allergan appeared first on NASDAQ.